Clinical Study
Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
Table 6
(a) Primer sequence for qPCR. (b) Primer sequence for methylation analyses.
(a) |
|
qPCR primer sequence |
| RASSF1A | Forward | 5′-GCTGAGCGTCACGGCCAAGT-3′ 5′-ATGCTGAAGGCGTCCCAGTT-3′ | Reverse |
| MAGEA-1 | Forward | 5′-TCCGCCTTTCCCACTACCAT-3′ 5′-TCCAGCATTTCTGCCTTTGT-3′ | Reverse |
| MAGEA-3 | Forward | 5′-GGAGTCCGAGTTCCAAGCAG-3′ 5′-AGGCAGGTGGCAAAGATGTA-3′ | Reverse |
| P15 | Forward | 5′-CAACGGAGTCAACCGTTTCGG-3′ 5′-CAGCACCACCAGCGTGTCCAG-3′ | Reverse |
| p16 | Forward |
5′-CTGGACACGCTGGTGGTGCT-3′ 5′-CTATGCGGGCATGGTTACTGC-3′ | Reverse |
| BRCA1 | Forward | 5′-AGAAACCACCAAGGTCCAAA-3′ 5′-CCAAGGGTGAATGATGAAAG-3′ | Reverse |
| β-Actin | Forward | 5′-AAAGACCTGTACGCCAACAC-3′ 5′-GTCATACTCCTGCTTGCTGAT-3′ | Reverse |
|
|
(b) |
|
Primer sequence |
| MAGEA-1 (M) | Forward | 5′-AGGAGGGGATAAATATTTGGTTATAC-3′ 5′-GCTCAAATCAATAAAAAAAACGTC-3′ | Reverse |
| MAGEA-1 (U) | Forward | 5′-AGGGGATAAATATTTGGTTATATGT-3′ 5′-CACTCAAATCAATAAAAAAAACATC-3′ | Reverse |
| MAGEA-3 (M) | Forward | 5′-GGTAGTATCGTTGTTAGGATGTGAC-3′ 5′-AACCCTCTATCTAAAATAAAACCCG-3′ | Reverse |
| MAGEA-3 (U) | Forward | 5′-GGTAGTATTGTTGTTAGGATGTGATG-3′ 5′-ACCCTCTATCTAAAATAAAACCCAC-3′ | Reverse |
|
|